What is the Oncotype DX® Breast cancer test?

The Oncotype DX® Breast cancer test is an unique genetic diagnostic test that can help doctors make a more informed, personalised treatment plan for their breast cancer patients. In practice it means, that the test looks at the expression of 21 cancer related genes within a patient's tumour sample and based on these tests it provides a numerical figure (Recurrence score) that predicts the possibility of the cancer returning. In addition, the Oncotype DX® Breast cancer test provides information that helps the doctors to distinguish between the patients that will benefit from chemotherapy and the patients for whom the chemotherapy is unnecessary and only burdens their organism.

Who is Eligible?

The Oncotype DX® should be recommended for patients recently diagnosed with breast cancer in early stage, oestrogen-receptor-positive (ER+) and Human Epidermal growth factor Receptor 2-negative (HER2-), when the decision about chemotherapy has to be made.

What does it mean to be ER+?

ER+ stands for oestrogen receptor positive. Oestrogen is one of many hormones in your body and it has many roles. Some cells in your breasts contain oestrogen receptors, which are activated by oestrogen. If the cancer cells in your breast have oestrogen receptors, it is classified as "ER+." Likewise, if they do not, the cancer would be classified as "ER-." Patients with ER+ breast cancer may qualify for the Oncotype DX® breast cancer test.

What does HER2 mean?

HER2 is a gene responsible for certain cancers. HER2 stands for Human Epidermal growth factor Receptor 2. If your breast cancer is tested for HER2 status, the results will be given as positive (HER2+) or negative (HER2-). Only patients with HER2-negative breast cancer qualify for the Oncotype DX® breast cancer test.

Is the Oncotype DX® test reimbursed? And where can I ask for it?

Oncotype DX® test is reimbursed from the major health insurer in Czech Republic VZP for their customers within the decision about the optimal treatment for patients with Early Breast Cancer hormonal positive, HER2 negative with Grade 2 and one of risk factors (high Ki67). Reimbursement is restricted to Cancer Centers. Thanks to the increasing interest in OncotypeDX Breast Cancer Test other insurance companies gradually begin to reimburse the test as well. For more information contact us via info@xeneo.cz

A current list of cancer centers where you can ask for the test:

Nemocnice Jihlava p.o.
Vrchlického 59, 58 633, Jihlava

Všeobecná fakultní nemocnice v Praze
U nemocnice 499/2, 128 08, Praha 2

Multiscan s.r.o.
Kyjevská 44, 530 03 Pardubice

Fakultní nemocnice Plzeň
Edvarda Beneše 1128/13, 305 99, Plzeň

Tomayerova nemocnice
Vídeňská 800, 140 59, Praha 4 – Krč

Masarykův Onkologický Ústav
Žlutý kopec 7, 656 53, Brno

Nemocnice Nový Jičín a.s.
Purkyňova 2138/16, 741 01, Nový Jičín

Krajská zdravotní a.s.
Sociální péče 3316, 401 13, Ústí nad Labem

Fakultní nemocnice Hradec Králové
Sokolská 581, 500 05, Hradec Králové

Fakultní nemocnice v Motole
V Úvalu 84, 150 06, Praha 5

Fakultní nemocnice Brno
Jihlavská 20, 625 00, Brno

Krajská nemocnice Tomáše Bati Zlín
Havlíčkovo nábřeží 600, 762 75, Zlín

Can I ask for the test even in case my insurance company doesn't cover these expenses?

Yes, in this case you can participate in Care Program. Within Care Program you can ask for the test (in some oncological centres) or you can buy the test by yourself.

For more information please contact us on info@xeneo.cz